@entity1665 is the most common type of hair loss in @entity1 and @entity1 . The disorder represents a quantitative phenotype with an underlying genetic disposition. So far none of the causative genes have been identified. Under the influence of @entity3800 there is a shortening of the anagen phase as well as a reduction of the cellular hair matrix volume in the involved scalp area. This results in the transformation of thick terminal hair follicles into thin vellus-like hair follicles. Clinically, @entity1 present with an @entity1665 that follows a defined pattern ( @entity1665 ) and progresses continuously but in varying degrees. In advanced cases, @entity1 may develop @entity1665 with remaining hair exclusively in the temporal and occipital regions. @entity1 are prone to exhibit a more diffuse type of hair loss with pronounced thinning in the parietal region. Whereas the diagnosis of @entity1665 is easy, its treatment is often difficult. The physician is commonly confronted with high @entity1 ' expectations regarding hair regrowth. Today, with @entity5491 and @entity585 , effective therapies are available which can lead to cessation of hair loss. The identification of underlying genes will make a more specific therapy easier to achieve.

[ XXXX . Current aspects of a common phenotype].

@entity1665 :: ('MESH:D000505', 'Disease') :: ['baldness', 'pattern baldness', 'androgenetic alopecia', 'alopecia', 'Androgenetic alopecia'] @entity1 :: ('9606', 'Species') :: ['women', 'patients', 'Women', 'men'] @entity585 :: ('MESH:D018120', 'Chemical') :: ['finasteride'] @entity5491 :: ('MESH:D008914', 'Chemical') :: ['minoxidil'] @entity3800 :: ('MESH:D000728', 'Chemical') :: ['androgens']
@entity1665 :: (MESH:D000505,Disease) :: ['Androgenetic alopecia']
